Sanofi has finalized its acquisition of Vigil Neuroscience, Inc., a move that adds to Sanofi’s research and development efforts in neurology. The deal brings VG-3927, an oral small-molecule TREM2 agonist, into Sanofi’s early-stage pipeline. This compound is set for evaluation in a phase 2 clinical study involving patients with Alzheimer’s disease. The acquisition also includes Vigil’s preclinical pipeline, which is expected to support Sanofi’s ongoing work on neurodegenerative diseases.
In June 2024, Sanofi invested $40 million in Vigil Neuroscience. That investment included exclusive negotiation rights related to VG-3927, covering potential research, development, manufacturing, and commercialization.
Under the terms of the agreement, Sanofi acquired all outstanding common shares of Vigil for $8 per share in cash at closing. This values Vigil at approximately $470 million on a fully diluted basis. Shareholders of Vigil will also receive a non-transferable contingent value right (CVR) per share, entitling them to a deferred cash payment of $2 if VG-3927 achieves its first commercial sale.
Vigil’s other clinical program, VGL101, was not part of the acquisition. According to Sanofi, “the acquisition of Vigil is not expected to impact Sanofi’s financial guidance for 2025.”
Sanofi describes itself as an R&D-driven biopharma company focused on developing medicines and vaccines for global health needs. The company states: “We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time.”
The company remains listed on EURONEXT under SAN and NASDAQ under SNY.
Sanofi cautions that forward-looking statements in this announcement are subject to risks and uncertainties. These include factors such as outcomes from future clinical data or regulatory decisions that may affect product approval or commercial success.
